Clinical trial NCT04213794: Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
Official title: A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: EARLY_PHASE1
Conditions: Malignant Abdominal Neoplasm
Malignant Pelvic Neoplasm
Recurrent Colon Carcinoma
Recurrent Desmoplastic Small Round Cell Tumor
Recurrent Fallopian Tube Carcinoma
Recurrent Gastric Carcinoma
Recurrent Liposarcoma
Recurrent Malignant Mesothelioma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Recurrent Rectal Carcinoma
Recurrent Rhabdomyosarcoma
Recurrent Sarcoma
Refractory Colon Carcinoma
Refractory Desmoplastic Small Round Cell Tumor
Refractory Fallopian Tube Carcinoma
Refractory Gastric Carcinoma
Refractory Liposarcoma
Refractory Malignant Mesothelioma
Refractory Ovarian Carcinoma
Refractory Primary Peritoneal Carcinoma
Refractory Rectal Carcinoma
Refractory Rhabdomyosarcoma
Refractory Sarcoma
Resectable Liposarcoma
Resectable Malignant Mesothelioma
Resectable Sarcoma
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2019-12-30
Enrollment: 2
Sex: ALL
Minimum age (years): 1
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This early phase I trial studies how well heated intra-peritoneal chemotherapy with doxorubicin and cisplatin work for the treatment of abdominal or pelvic tumors that can be removed by surgery (resectable), does not respond to treatment (refractory), or has come back (recurrent). Heated intra-peritoneal chemotherapy is a procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity. Chemotherapy drugs, such as doxorubicin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more cells.

Detailed description: PRIMARY OBJECTIVES:

I. To assess the feasibility of heated intra-peritoneal chemotherapy (HIPEC) with doxorubicin (DOXO) and cisplatin (CDDP) after surgical resection of pediatric pelvic and abdominal tumors.

II. To assess morbidity, hospital length of stay and peri-operative mortality outcomes for pediatric patients with intraperitoneal sarcoma undergoing hyperthermic intraperitoneal chemotherapy.

SECONDARY OBJECTIVE:

I. To assess complications and adverse events of HIPEC. II. Evaluate disease recurrence patterns: locoregional versus distant. III. Evaluate disease progression defined by radio-graphically visible nodules greater than 1.5 cm.

OUTLINE:

Patients undergo cytoreduction. Patients also undergo HIPEC over 60 minutes consisting of doxorubicin and cisplatin. Patients then receive sodium thiosulfate intravenously (IV) over 12 hours.

After completion of the study treatment, patients are followed every 6 months for 5 years.

Eligibility criteria: Inclusion Criteria:

* Patients must have resectable, primary refractory or recurrent intra-abdominal or pelvic tumors based on imaging studies with measurable disease (\>= 1 cm in 2 perpendicular planes), or primary tumor with peritoneal implants in whom no known other curative treatment exists, and/or patients not on up-front clinical trial
* Evidence of macroscopic or microscopic intra-peritoneal seeding (separate from the primary tumor) identified at the time of exploratory surgery with or without primary tumor resection
* Peritoneal cancer index (PCI) =\< 20 and surgeons deem high likelihood of complete residual tumor stage R0 (R0) resection
* No evidence of distant metastases at the time of enrollment
* Histologies to be considered include: rhabdomyosarcoma, liposarcoma, sarcoma (other), ovarian cancer, fallopian tube cancer, gastric cancer, colon cancer, rectal cancer, mesothelioma, and desmoplastic small-round-cell tumor
* Patients must be 1-25 years of age at the time of entry into the study
* Patients may be included in the study independent of the regimen of previous surgical, radiation, or chemotherapy treatments administered. Given the increased risk of entero-cutaneous fistulae observed in patients treated with HIPEC AFTER radiation therapy, patients will be assessed for risk by radiation oncology
* Karnofsky / Lansky performance score of \>= 40 or Eastern Cooperative Oncology Group (ECOG) performance score of 3 or less
* Platelet count \>= 50,000 (independent of transfusion) (performed no later than 14 days before surgery)
* Prothrombin and partial thromboplastin times =\< 1.2 X normal (performed no later than 14 days before surgery)
* Total bilirubin =\< 2 X normal (performed no later than 14 days before surgery)
* Serum glutamic-oxaloacetic transaminase (SGOT) =\< 2 X normal (performed no later than 14 days before surgery)
* Serum glutamate pyruvate transaminase (SGPT) =\< 2 X normal (performed no later than 14 days before surgery)
* Lactate dehydrogenase (LDH) =\< 2 X normal (performed no later than 14 days before surgery)
* Alkaline phosphatase =\< 2 X normal (performed no later than 14 days before surgery)
* Neutrophil count \>= 750 (performed no later than 14 days before surgery)
* Patients must have adequate renal function defined as creatinine clearance (performed no later than 14 days before surgery) or radioisotope GFR (glomerular filtration rate) \>= 70 mL/min/1.73 m\^2 or a serum creatinine based on age/gender less than the following values:

  * 1 to \< 2 years 0.6mg/dL for both males and females
  * 2 to \< 6 years 0.8mg/dL for both males and females
  * 6 to \<10 years 1.0mg/dL for both males and females
* A signed informed consent form (and assent form when appropriate) approved by the Mayo Clinic (Institutional Review Board \[IRB\]) will be required for patient enrollment into the study. Patients must be able to read and understand the informed consent document and must sign the informed consent indicating that they are aware of the investigational nature of this study

Exclusion Criteria:

* Females who are pregnant or breast-feeding during the study period will be excluded
* Distant metastatic disease not limited to peritoneum:

  * Solid organ metastases (liver, central nervous system, lung)
  * Known bone marrow involvement
* No critical cumulative dose of previous chemotherapy (total anthracycline dose not \>= 435 mg / m\^2)
* Prior HIPEC within 3 months
* Patients with an active infection requiring treatment or having an unexplained febrile illness (Tmax \> 99.5 Fahrenheit \[F\]), patients with known immune deficiency disorder or known human immunodeficiency virus infection
* Patients must not have any systemic illness which precludes them from being an operative candidate as determined by anesthesia preoperative evaluation. This includes but is not limited to, sepsis, liver failure, renal failure, cardiovascular failure, pulmonary failure
* Subjects deemed unable to comply with study and/or follow-up procedures
* Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacitation

Primary outcomes:
measure: Incidence of adverse events of cytoreductive surgery (CRS) with heated intra-peritoneal chemotherapy (HIPEC) in this patient population
timeFrame: Up to 6 months
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: From the time of diagnosis of cancer up, assessed to 5 years
measure: Disease-free survival (DFS)
timeFrame: From the time of diagnosis of cancer up to 5 years
measure: Peritoneal-free recurrence
timeFrame: From the time of diagnosis of cancer up to 5 years
measure: Incidence of morbidity
timeFrame: 30, 60, and, 90 days post-HIPEC procedure
measure: Incidence of mortality
timeFrame: 30 days post-HIPEC procedure
measure: Hospital length of stay
timeFrame: Up to 5 years
measure: Estimated blood loss (EBL)
timeFrame: Up to 5 years
measure: Operative time
timeFrame: Up to 5 years
measure: Progression free survival (PFS)
timeFrame: From the time protocol treatment is initiated, assessed up to 5 years
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Patricio C. Gargollo, M.D.
role: PRINCIPAL_INVESTIGATOR
References: